Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?
- 2 October 2025
- journal article
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 46 (11) , 2324-2329
Abstract
BACKGROUND AND PURPOSE: Amyloid-related imaging abnormalities (ARIA) are common complications of antiamyloid immunotherapy for Alzheimer disease (AD). Identifying imaging biomarkers that predict ARIA risk may help guide treatment decisions. This study investigates the relationship between deep white matter hyperintensities (DWMH), perivascular spaces (PVS), and ARIA incidence in patients with AD treated with lecanemab. MATERIALS AND METHODS: This retrospective cohort study included 27 ARIA-positive patients identified between November 2023 and November 2024, and 27 age- and sex-matched ARIA-negative controls. Baseline MRI was assessed for DWMH burden (Fazekas score) and PVS grades in the basal ganglia and centrum semiovale. Simple logistic regression was performed to evaluate associations between imaging markers and ARIA risk. RESULTS: ARIA-positive patients had significantly higher Fazekas scores compared with ARIA-negative patients (1.37 versus 1.0; P = .0262), indicating a greater DWMH burden. PVS grades in the basal ganglia were numerically higher in ARIA-positive patients (1.81 versus 1.56, P = .0733) but did not reach statistical significance. Simple logistic regression identified the Fazekas score as a significant predictor of ARIA (OR: 2.812; 95% CI, 1.076–8.438; P = .0343). The area under the receiver operating characteristic curve for the model was 0.640 (95% CI, 0.492–0.788; P = .078). CONCLUSIONS: Higher DWMH burden, as quantified by the Fazekas score, is significantly associated with ARIA risk in patients with AD treated with lecanemab. These findings suggest that DWMH may serve as a potential imaging biomarker for ARIA risk stratification. Larger studies incorporating additional vascular biomarkers, including cerebral amyloid angiopathy markers, are warranted to refine risk prediction models. Graphical AbstractKeywords
This publication has 21 references indexed in Scilit:
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2023
- Perivascular space dilation is associated with vascular amyloid-β accumulation in the overlying cortexActa Neuropathologica, 2021
- Alzheimer Disease: An Update on Pathobiology and Treatment StrategiesCell, 2019
- A critical appraisal of amyloid-β-targeting therapies for Alzheimer diseaseNature Reviews Neurology, 2019
- Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegenerationThe Lancet Neurology, 2013
- Mechanisms of sporadic cerebral small vessel disease: insights from neuroimagingThe Lancet Neurology, 2013
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable WorkgroupAlzheimer's & Dementia, 2011
- Imaging of amyloid burden and distribution in cerebral amyloid angiopathyAnnals of Neurology, 2007